Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY3502970 in Healthy Overweight and Obese Participants
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT05313802
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
🇺🇸Qps-Mra, Llc, Miami, Florida, United States
🇺🇸ICON Early Phase Services Lenexa Center, Lenexa, Kansas, United States
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 400
- Registration Number
- NCT05307705
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸DFCI, Boston, Massachusetts, United States
🇺🇸Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
A Study of LY3841136 in Healthy and Overweight Participants
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 148
- Registration Number
- NCT05295940
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study of LY3857210 in Healthy Participants
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 10
- Registration Number
- NCT05292040
- Locations
- 🇺🇸
Invicro, Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
- Conditions
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 900
- Registration Number
- NCT05288166
- Locations
- 🇺🇸
AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇲🇽Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo León, Mexico
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
- Conditions
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 986
- Registration Number
- NCT05275400
- Locations
- 🇺🇸
Diabetes Associates Medical Group, Orange, California, United States
🇺🇸Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States
🇺🇸SKY Clinical Research Network Group - Hall, Fayette, Mississippi, United States
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 25
- Registration Number
- NCT05262387
- Locations
- 🇨🇦
LMC Clinical Research Inc. (Bayview), Toronto, Ontario, Canada
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 99
- Registration Number
- NCT05260021
- Locations
- 🇮🇱
Soroka Medical Center, Be'er Sheva, HaDarom, Israel
🇮🇱Yitzhak Shamir Medical Center, Beer Yaacov, HaMerkaz, Israel
🇫🇷Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Robert Debre - Centre Hospitalo Universitaire (C -T, Paris, France
A Study of LY3561774 in Participants With Mixed Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 204
- Registration Number
- NCT05256654
- Locations
- 🇲🇽
Unidad Médica para la Salud Integral, San Nicolás de los Garza, Nuevo León, Mexico
🇵🇱Niepubliczny Zakład Opieki Zdrowotnej "Przychodnia z Sercem", Grojec, Małopolskie, Poland
🇨🇦North York Diagnostic and Cardiac Centre, North York, Ontario, Canada
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 110
- Registration Number
- NCT05241834
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States